Plain-English translation of NCT06714903 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is trying to understand how the bacteria in your gut may affect how well immunotherapy works for advanced colorectal cancer. Researchers will collect stool and blood samples from you before and after you receive treatment with sintilimab (a type of immunotherapy) combined with fruquintinib. By studying these samples, scientists hope to identify which gut bacteria help or hurt the effectiveness of this medication.
Some patients respond very well to immunotherapy for colorectal cancer, while others don't respond as well—and doctors don't fully understand why. This study exists to discover whether the bacteria naturally living in your gut play a role in determining how effective the treatment will be, which could one day help predict who will benefit most from this medication.
You will provide stool and blood samples before starting treatment and again after one cycle of immunotherapy—these are stored in a freezer for later analysis. Six months after beginning treatment with the medication, you will have imaging scans to see how well the treatment is working. Researchers will then analyze your samples to understand how your gut bacteria may have influenced your response to the treatment.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China
Sponsor
The First Hospital of Jilin University
Enrollment target
~50 participants
Started
July 2024
Primary completion
December 2025
Age range
35 Years – 75 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nan Zhang
The First Hospital of Jilin University